We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Plans Advisory Committee Meetings for Oncology Accelerated Approvals in Ongoing Review
FDA Plans Advisory Committee Meetings for Oncology Accelerated Approvals in Ongoing Review
As part of an industry-wide FDA review, the agency’s Oncologic Drugs Advisory Committee will convene next month to discuss six cancer indication approvals given under the agency’s Accelerated Approval program that haven’t verified their clinical benefit in confirmatory trials as required.